Tirzepatide is an investigational peptide specifically developed as a dual receptor agonist, targeting both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Its combined mechanism of action is of growing interest within research focused on metabolic disorders, obesity, and insulin resistance. Research Applications: Emerging data from preclinical and early clinical studies suggest that Tirzepatide…